Abstracts Archive - Page 2179 of 2425 - ACR Meeting Abstracts

Abstract Number: 1068 • 2013 ACR/ARHP Annual Meeting
An In-Depth Analysis Of The Prevalence and Socio-Demographic Factors Associated With Lupus Nephritis In Major Industrialized Countries
Guiping Yang and Anne Tuomari, Global Health Economics and Outcome Research, Teva Pharmaceuticals, Inc., Frazer, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a complex autoimmune disease with incidence and prevalence well studied and documented worldwide. Lupus nephritis (LN) is a severe…
Abstract Number: 1052 • 2013 ACR/ARHP Annual Meeting
Glucocorticosteroids and Mortality Risk In Rheumatoid Arthritis – Results Of a Population Based Study
Diane Lacaille¹, J. Antonio Avina-Zubieta^2,3, Eric C. Sayre², Michal Abrahamowicz⁴ and John Esdaile^1,5, ¹Rheumatology, Arthritis Research Centre of Canada, University of British Columbia, Richmond, BC, Canada, ²Arthritis Research Centre of Canada, Richmond, BC, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada, ⁵Medicine, University of British Columbia, Vancouver, BC, Canada
Background/Purpose: Glucocorticosteroids (GC) are frequently used in the management of rheumatoid arthritis (RA). Due to their metabolic and immunosuppressive effects, they could increase the risk…
Abstract Number: 1053 • 2013 ACR/ARHP Annual Meeting
Physician Proclivity To Use Oral Glucocorticoids Among Rheumatoid Arthritis Patients
Huifeng Yun¹, Fenglong Xie², Elizabeth S. Delzell¹, Lang Chen³, Emily Levitan¹, James Lewis⁴, Kenneth G. Saag⁵, Timothy Beukelman⁶, Kevin L. Winthrop⁷, John Baddley⁸ and Jeffrey R. Curtis⁹, ¹Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁶Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷Dept of Infectious Disease, Oregon Health & Science University, Portland, OR, ⁸Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁹University of Alabama at Birmingham, Division of Clinical Immunology and Rheumatology, Birmingham, AL
Background/Purpose: It is unclear if the elevated risks of adverse events in rheumatoid arthritis (RA) patients are due to use of biologics or DMARDs, glucocorticoids…
Abstract Number: 1054 • 2013 ACR/ARHP Annual Meeting
Use Of Oral and Subcutaneous MTX In a Commercially Insured Rheumatoid Arthritis Population
Jeffrey R. Curtis¹, Fenglong Xie², Jie Zhang³, Lang Chen⁴, Huifeng Yun⁵, Michael H. Schiff⁶, Timothy Beukelman⁷ and Seth Ginsberg⁸, ¹University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁵Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁶Rheumatology Division, University of Colorado, Denver, CO, ⁷Pediatric Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁸Creaky Joints, New York, NY
Background/Purpose: Methotrexate (MTX) is the most commonly used medication in rheumatoid arthritis (RA), although use of oral and subcutaneous (SQ) preparations in real-world settings has…
Abstract Number: 1055 • 2013 ACR/ARHP Annual Meeting
Discontinuation Rates In Patients With RA Of Triple Disease Modifying Antirheumatic Therapy
Sofia Pedro¹, Frederick Wolfe¹, Hawre Jalal² and Kaleb Michaud³, ¹National Data Bank for Rheumatic Diseases, Wichita, KS, ²Health Polisy and Management, University of Minnesota, Minneapolis, MN, ³Rheumatology, National Data Bank for Rheumatic Diseases & University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Drug discontinuation rates are measures of effectiveness and are needed in health economic models. While a recent RCT demonstrated statistical equivalence of efficacy with…
Abstract Number: 1056 • 2013 ACR/ARHP Annual Meeting
Adherence To Methotrexate Therapy Among Patients With Rheumatoid Arthritis In Denmark: A Registry Based Cohort Study
Henning Bliddal¹, Robin Christensen², Mikkel Østergaard³, Tove Lorenzen⁴, Michael Sejer Hansen⁵, Peter Vestergaard⁶ and Stine A Eriksen⁶, ¹The Parker Institute, Copenhagen, Denmark, ²Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, The Parker Institute, Department of Rheumatology, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Denmark, Frederiksberg, Denmark, ³Copenhagen University Hospital Glostrup, Copenhagen, Denmark, ⁴Department of Rheumatology, Region Hospital Silkeborg, Silkeborg, Denmark, ⁵Gildhøj Privathospital, Copenhagen, Denmark, ⁶Medicine, Aalborg University, Aalborg, Denmark
Background/Purpose: Conflicting data have been presented on patient compliance with methotrexate (MTX) prescription. A Danish study found a mean period of 12.3% of the prescribed…
Abstract Number: 1057 • 2013 ACR/ARHP Annual Meeting
Regional Variations In Rheumatoid Arthritis Treatment and Health Outcomes Across The United States
Susan C. Bolge¹, Roxanne Meyer² and Kathy Annunziata³, ¹Janssen Scientific Affairs, LLC, Horsham, PA, ²Janssen Scientific Affairs, LLC, Horsham, NY, ³Kantar Health, Princeton, NJ
Background/Purpose: Current ACR guidelines call for treatment of rheumatoid arthritis (RA) with non-biologic or biologic disease modifying anti-rheumatic drugs (DMARDs). The National Quality Forum has…
Abstract Number: 1058 • 2013 ACR/ARHP Annual Meeting
Concomitant Methotrexate Use and The Risk Of Drug Discontinuation For Adalimumab Compared With Etanercept In Anti-TNF-Naïve Rheumatoid Arthritis Patients: A Nationwide Population-Based Cohort Study
Hsin-Hua Chen^1,2, Der-Yuan Chen¹, Chao-Hsiung Tang³, Ya-Wen Yang⁴, Chi-Hui Fang⁴ and Nicole Huang⁵, ¹Division of Allergy, Immunology and Rheumatology, Department of Internal Medicine, Taichung Veterans General Hospital, Taichung, Taiwan, ²nstitute of Public Health and Community Medicine Research Center, National Yang-Ming University, Taipei, Taiwan, ³Taipei Medical University, Taipei, Taiwan, ⁴Pfizer Limited, Taipei, Taiwan, ⁵Institute of Hospital and Health Care Administration, National Yang-Ming University, Taipei, Taiwan
Background/Purpose: To evaluate possible interaction effect by concomitant methotrexate (MTX) use on the risk of drug discontinuation for adalimumab (ADA) compared with etanercept (ETN) in…
Abstract Number: 1060 • 2013 ACR/ARHP Annual Meeting
Perinatal Risk Factors For Systemic Lupus: A Register-Based Case-Control Study
Elizabeth V. Arkema¹ and Julia F. Simard^2,3, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Depts of Health Research and Policy and Immunology & Rheumatology, Stanford University School of Medicine, Stanford, CA, ³Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: One’s own fetal environment has been linked to future heart disease, breast cancer, and rheumatoid arthritis. Prior work showed that among older women in…
Abstract Number: 1061 • 2013 ACR/ARHP Annual Meeting
Clinical Phenotypes and Disease Burden Of Discoid Lupus Erythematosus In a Sample Of Systemic Lupus Erythematosus Patients In The Southeastern United States
Leslie Anne Cassidy¹, Gaobin Bao², Charmayne M. Dunlop-Thomas³, S. Sam Lim⁴ and Cristina Drenkard^5,6, ¹Department of Medicine, Division of Rheumatology, Emory University, Atlanta, GA, ²Medicine, Emory University, Atlanta, GA, ³Medicine Rheumatology, Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, ⁵Department of Medicine, Emory University, Atlanta, GA, ⁶Epidemiology, Emory Rollins School of Public Health, Atlanta, GA
Background/Purpose: The rash of discoid lupus erythematosus (DLE) has been reported in 10-25% of patients with systemic lupus erythematosus (SLE). Prior reports suggest that DLE…
Abstract Number: 1062 • 2013 ACR/ARHP Annual Meeting
The Brief Index Of Lupus Damage As a Predictor Of Mortality In a Cohort Of Patients With Systemic Lupus Erythematosus
Stephanie Rush¹, Laura Trupin², Jinoos Yazdany² and Patricia P. Katz², ¹University of California, San Francisco, San Francisco, CA, ²Medicine, University of California, San Francisco, San Francisco, CA
The Brief Index of Lupus Damage as a Predictor of Mortality in a Cohort of Patients with Systemic Lupus Erythematosus Background/Purpose: To examine whether a…
Abstract Number: 1063 • 2013 ACR/ARHP Annual Meeting
The Influence Of Socioeconomic and Race In Damage Score In Patients With Systemic Lupus Erythematosus
Roberto Teixeira¹, Eduardo F. Borba², Georges Christopoulos Sr.³ and Emilia Sato⁴, ¹UNIVERSIDADE FEDERAL DE SÃO PAULO, SAO PAULO, Brazil, ²Rheumatology Division; University of São Paulo, São Paulo, Brazil, ³SANTA CASA DE MISERICORDIA DE MACEIO, MACEIO, Brazil, ⁴Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
Background/Purpose: The association between socioeconomic status and damage in Systemic lupus erythematosus patients is confounded by the influence of race in various previous studies. The…
Abstract Number: 1064 • 2013 ACR/ARHP Annual Meeting
Trends In Hospitalizations Due To Organ Damage In Patients With Systemic Lupus Erythematosus In Canada, 2006-2010
Amyn Sayani¹, Neerav Monga², Marni Freeman² and Jorge Alfonso Ross Terres³, ¹Medical Affairs, GlaxoSmithKline, Mississauga, ON, Canada, ²Health Economics and Outcomes Research, Medical Division, GlaxoSmithKline, Inc., Mississauga, ON, Canada, ³Medical Affairs, GlaxoSmithKline, Inc., Mississauga, ON, Canada
Background/Purpose: Systemic Lupus Erythematosus (SLE) is an autoimmune disease that can affect multiple organs in the body, including the heart, kidney and lung, leading to…
Abstract Number: 1065 • 2013 ACR/ARHP Annual Meeting
Acute Myocardial Infarction Variation Among U.S. Medicaid Recipients With Systemic Lupus Erythematosus By Race and Ethnicity, 2000-2006
Medha Barbhaiya¹, Candace H. Feldman¹, Jessica M. Franklin², Jun Liu³, Joanne M. Foody⁴, Michael A. Fischer², Daniel H. Solomon¹ and Karen H. Costenbader¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital, Boston, MA, ³Division of Pharmaoepidemiology, Brigham and Women's Hospital, Boston, MA, ⁴Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA
Background/Purpose: SLE patients have elevated rates of acute myocardial infarctions (MI), but the sociodemographic groups that are most affected have not been well studied. We…
Abstract Number: 1066 • 2013 ACR/ARHP Annual Meeting
Depression Screening In Patients With Systemic Lupus Erythematosus From The Southeastern United States: Missing Opportunities For Early Diagnosis and Treatment
Cristina Drenkard¹, Charmayne M. Dunlop-Thomas², Gaobin Bao³ and S. Sam Lim⁴, ¹Department of Medicine, Emory University, Atlanta, GA, ²Medicine Rheumatology, Emory University, Atlanta, GA, ³Medicine, Emory University, Atlanta, GA, ⁴Emory University School of Medicine, Division of Rheumatology, Atlanta, GA
Background/Purpose: Depression can be found in 20-60% of SLE patients and has substantial impact on quality of life, disease outcomes and health care costs. Although…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].